


ABSTRACT

The present invention relates to novel oxazolidinone derivatives represented as following compound I and a process for the preparation thereof. The compounds of the present invention have wide antibacterial spectrum, superior antibacterial activity and low toxicity. Therefore, it can be expected to use as novel antibacterial agent.

[compound I]



wherein, R_1 is alkylcarboxyl group or $-CH_2R_2$ (wherein, R_2 is OH, argido group, $-OR_3$ (wherein, R_3 is C_{1-4} alkyl, methansulfonyl, p-toluensulfonyl, carboxyl, C_{1-4} alkylcarboxyl, C_{1-4} alkylcarbonyl, benzyloxycarbonyl, or imidazolylcarbonyl), or $-NHR_4$).

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066648 A1

(51) International Patent Classification⁷: **C07H 15/22**

Hun, Yeong [KR/KR]; #110-701 SK Bukhansancity Apt.,
1353 Mia7-dong, Kangbuk-ku, 142-107 Seoul (KR).

(21) International Application Number: PCT/KR02/01268

(74) Agent: **LEE, Won-Hee**; 8th Fl., Sung-ji Heights II,
642-16, Yoksam-dong, Kangnam-ku, 135-080 Seoul (KR).

(22) International Filing Date: 4 July 2002 (04.07.2002)

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:
2002-7495 8 February 2002 (08.02.2002) KR

(71) Applicant (*for all designated States except US*): **KOREA
INSTITUTE OF SCIENCE AND TECHNOLOGY**
[KR/KR]; 39-1 Hawolkok-dong, Sungbuk-ku, 136-130
Seoul (KR).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **YU, Jaehoon**
[KR/KR]; #102-1403 Kukdonggreen Apt., 436 Ok-
soo-dong, Sungdong-ku, 133-759 Seoul (KR). **LEE,
Jongkook** [KR/KR]; #4-806 JoongangHwakok-Heights
Apt., 351-89 Hwakok7-dong, Kangseo-ku, 157-882 Seoul
(KR). **KWON, Miyun** [KR/KR]; #102-105 Hyundai
Apt., Jamwon-dong, Seocho-ku, 137-030 Seoul (KR).
PAE, Ae,Nim [KR/KR]; #2-405 Jangmi Apt., 7 Shin-
cheon-dong, Songpa-ku, 138-240 Seoul (KR). **KOH,**

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: HETERODIMERIC CONJUGATES OF NEOMYCIN-OXAZOLIDINONE, THEIR PREPARATION AND THEIR USE



(1)

(57) Abstract: The present invention relates to heterodimeric conjugates of neomycin-oxazolidinone of formula 1, their preparation and their use. Because of their heterodimeric structure, they can recognize both stems and loops of the RNA motif and show a strong binding force to certain RNAs. Accordingly, they can be effectively used as an antiviral agent or an antibacterial agent with enhanced pharmaceutical efficacy and reduced side effect. Formula (1) Wherein, Ac and n are as defined in the description.